ACE研究将指导心血管疾病全面防治的新策略PPT.pptVIP

Professor Rury Holman University of Oxford, UK Professor Chang Yu Pan Professor Da Yi Hu Chinese PLA General Hospital University of Peking China China;Rationale for ACE Trial;ACE Trial Management;Study Design;Rury Holman UK Diabetologist (Chair) DaYi Hu China Cardiologist (Co-Chair) ChangYu Pan China Diabetologist (Co-Chair) JiaLun Chen China Diabetologist (Honoured adviser) Juliana Chan Hong Kong Diabetologist Jean-Louis Chiasson Canada Diabetologist JunBo Ge China Cardiologist Hertzel Gerstein Canada Diabetologist John McMurray UK Cardiologist Lars Rydén Sweden Cardiologist Michal Tendera Poland Cardiologist Jaakko Tuomilehto Finland Epidemiologist WenYing Yang China Diabetologist Joanne Keenan UK DTU Project Manager Dieter Neuser Germany Bayer Project Manager Thorsten Petruschke Germany Bayer Project Manager;ACE Primary Endpoint;New-onset type 2 diabetes, confirmed by two successive diagnostic plasma glucose values FPG ≥7.0 mmol/l and/or 2HPG ≥11.1 mmol/l ;All cause mortality Extended CVD endpoint of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, fatal or non-fatal stroke and hospitalisation for heart failure or for unstable angina. Each component will also be analysed individually Evidence of non-alcoholic fatty liver disease (NAFLD) as judged by ALT changes Development of impaired renal function (eGFR 60 ml/minute/1.73 m2) or doubling of baseline creatinine Health Economic evaluation;Sample Size Estimation;Double Blind Intervention;ACE Study Flow Chart;Optimisation of Cardiovascular Therapy;Safety;The ACE trial is enrolling ~150 cardiovascular centres in Mainland China and Hong King Each centre is expected to recruit approximately 50 patients (minimum of 35 patients) Recruitment is competitive and will close when 7,500 patients have been randomised The ACE trial results are expected in 2014;Clinical Centre Requirements Qualified research staff and appropriate facilities to safely and properly conduct the trial